Related Experiment Videos
Cancer therapy by gene therapy with angiostatin
Goichi Matsumoto1, Junichi Shindo
1First Department of Oral and Maxillofacial Surgery, Kanagawa Dental College, Yokosuka, Kanagawa, Japan. gmatsu@kdcnet.ac.jp
Abstract:
Angiostatin, an internal fragment of plasminogen, has been shown to inhibit angiogenesis. A new area of cancer research that has generated excitement is the use of angiostatin to treat cancer. Angiostatin protein therapy has not been pursued because current technology is inadequate to manufacture the needed biologically active proteins in sufficient quantities. It is sufficient for effective therapy with angiostatin to establish angiostatin production in the vicinity of tumors by gene transfer of angiostatin cDNA. There are various methods by which to transfer angiostatin cDNA. One way is to use a viral vector to incorporate the gene into cells. Another way is to use nonviral vectors. In this review, evidence accumulated from many laboratories suggests that angiostatin gene therapy may be an important new cancer therapy as an adjuvant therapy to prevent recurrence. (c) 2001 Prous Science. All rights reserved.
Insights
Angiostatin gene therapy offers a promising new approach for cancer treatment by enabling localized production of angiostatin protein near tumors. This method overcomes manufacturing limitations for effective cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Angiostatin, a plasminogen fragment, inhibits angiogenesis, a key process in tumor growth.
- Current limitations in protein production hinder angiostatin therapy for cancer.
- Gene transfer offers a viable alternative for localized angiostatin production.
Purpose of the Study:
- To review the potential of angiostatin gene therapy for cancer treatment.
- To explore methods for delivering angiostatin cDNA for therapeutic purposes.
- To assess angiostatin gene therapy as an adjuvant treatment to prevent cancer recurrence.
Main Methods:
- Review of accumulated evidence from multiple laboratories.
- Discussion of gene transfer methods, including viral and nonviral vectors.
- Focus on establishing localized angiostatin production via gene transfer.
Main Results:
- Gene transfer allows for sufficient production of biologically active angiostatin near tumors.
- Both viral and nonviral vectors are potential delivery systems for angiostatin cDNA.
- Evidence suggests angiostatin gene therapy can be effective in cancer treatment.
Conclusions:
- Angiostatin gene therapy presents a novel and potentially effective strategy for cancer treatment.
- This approach may serve as an important adjuvant therapy to prevent tumor recurrence.
- Further research and development in gene delivery systems are warranted.